US5939564A - Process of lactonization in the preparation of statins - Google Patents

Process of lactonization in the preparation of statins Download PDF

Info

Publication number
US5939564A
US5939564A US09/055,572 US5557298A US5939564A US 5939564 A US5939564 A US 5939564A US 5557298 A US5557298 A US 5557298A US 5939564 A US5939564 A US 5939564A
Authority
US
United States
Prior art keywords
solvent
alcohol
solution
formula
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/055,572
Inventor
Yatendra Kumar
Rajesh Kumar Thaper
S. M. Dileep Kumar
Jag Mohan Khanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Assigned to RANBAXY LABORATORIES, LTD. reassignment RANBAXY LABORATORIES, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHANNA, JAG MOHAN, KUMAR, S.M. DILEEP, KUMAR, YATENDRA, THAPER, RAJESH KUMAR
Application granted granted Critical
Publication of US5939564A publication Critical patent/US5939564A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Definitions

  • the mild catalysts to be used in the instant invention are the salts of organic bases with inorganic or organic acids, such as pyridine hydrobromide, pyridine hydrochloride, or pyridine p-toluene sulfonate. Most preferably, pyridine hydrobromide is used.
  • the catalysts are used in small catalytic quantities ranging from 0.1 to 0.5 molar equivalents, preferably ranging from 0.1 to 0.25.
  • organic solvent in this invention refers to any lower alkanol or non-alcoholic polar solvent.
  • the lower alkanol includes those primary, secondary and tertiary alcohols having from one to six carbon atoms.
  • Suitable lower alcohol solvents also include methyl, ethyl, n-propyl, n-butyl, isobutyl and t-butyl alcohols.
  • the lower alkanol solvent used in the present invention will be methyl alcohol, isopropyl alcohol or isobutyl alcohol. Most preferably, isopropyl alcohol is used.
  • the amount of solvent is at least 1 part by volume per part of the starting material. Higher amounts of solvents and generally up to 30 parts by volume may be used. Amounts higher than 30 volumes are not useful from an economic point of view because large size reactors would be necessary.
  • the product obtained under the above defined conditions is highly crystalline and is easily filterable.
  • the product is very pure (>98% HPLC purity) with much less formation of impurities as compared to the prior art procedures. It does not require further purification.
  • the process is safe and environment friendly as very mild catalysts and non-drastic conditions are employed which are convenient for operation at a commercial scale.

Abstract

A novel process of lactonizaton in the preparation of statins (e.g., the HMG--CoA reductase inhibitors lovastatin and simvastatin) employs very mild reaction conditions. The improved process comprises dissolving the open ring hydroxy acid form of the statins in an organic solvent by heating at a temperature, which ranges from ambient to reflux of the solvent, under anhydrous conditions to produce a solution, treating the solution with a mild catalyst at a temperature from about ambient to 50° C., and adding water to the solution to cause the statins in lactone form to crystalize from the reaction mixture. The mild catalyst used in the reaction is a salt of an organic base with an organic or inorganic acid, such as pyridine hydrobromide, pyridine hydrochloride, or pyridinium, p-toluene sulfonate. The organic solvent comprises a lower alkanol, a non-alcoholic polar solvent, or a mixture of the two.

Description

BACKGROUND OF THE INVENTION
Lovastatin and its analogs, e.g., simvastatin, are potent antihyper-cholesterolemic agents that function by limiting cholesterol biosynthesis by inhibiting the enzyme HMG--CoA reductase. These compounds, which may be referred to generally as statins, are known to exist in open ring hydroxy acid and also in lactone form. The lactone form and the hydroxy acid form of these compounds have the following general structural Formulas: ##STR1## wherein Z is hydrogen, a metal cation, such as sodium or potassium, or NH4, and R is ##STR2## wherein R1 is H or CH3.
The open hydroxy acid form of the statins (Formula II) is the one which is biologically active. However, the statins are generally administered to a patient in the lactone form (Formula I), which is converted to its active metabolite, the hydroxy acid form, in the body.
In the process of manufacture of lovastatin and its analogs, e.g., simvastatin, the lactonization of free hydroxy acid or its salt to lactone form constitutes an essential step.
Processes known in the literature for the lactonization of the free hydroxy acid or its salts are either carried out under drastic heat conditions, i.e., refluxing with inert solvents, or catalyzed by strong acids when lactonization is effected at ambient temperature. The process disclosed in U.S. Pat. No. 4,820,850 involves heating the free acid or its salt, e.g., the ammonium salt, to reflux temperature (usually 100-110° C.) in high boiling hydrocarbon solvents such as toluene for 7-8 hours. The ambient acidity of the acid is believed to be responsible for the lactonization reaction at these high temperatures. In addition, water which is formed as a by-product of the reaction is continuously removed by azeotropic distillation, which forces the reaction to near completion. The process of lactonization under heat conditions of reflux temperatures is complicated by the formation of many impurities, of which dimer formation especially lowers the quality of the final lactone product. The dimer is a difficult-to-remove impurity and is present at the levels of 0.4 to 0.8% in the product. In order to minimize the dimer impurity, high dilutions are often used in the lactonization reaction at the cost of the efficiency of the reaction and of the process, which is disadvantageous at a commercial manufacturing scale.
U.S. Pat. No. 4,916,239 discloses another process wherein the lactonization reaction is carried out at room temperature by treating the free hydroxy acid ammonium salt of a mevinic acid in a mixture of acetic acid and water, and in the presence of a strong acid catalyst. After the free hydroxy acid-lactone equilibrium is established (reaction has proceeded to 50% conversion), water is gradually added in lots to effect crystallization of the lactone from the reaction medium. This removal of lactone continuously shifts the equilibrium to the lactone side thus leading to reaction completion. This process suffers from several disadvantages and is also not convenient to operate at a large scale for a variety of reasons, some of which are discussed below
Use of a strong mineral or an organic acid catalyst, e.g., formic, phosphoric, trifluoroacetic, sulphuric, hydrochloric, p-toluene sulphonic, methanesulphonic acids, etc., in quantities varying from 1.2 to 1.5 molar equivalents makes this process hazardous and environmentally unacceptable on an industrial scale. The excess acid catalyst which is used needs to be neutralized by adding a strong base before filtration of the product.
Furthermore, the lactonization reaction is only about 50% complete after the equilibrium is achieved. At this point in time, any fast or premature addition of water can lead to serious crystallization and filtration problems. Moreover, reaction and subsequent workup takes about 9-12 hours for completion, thereby decreasing the efficiency of the process.
The above-mentioned disadvantages make the process of U.S. Pat. No. 4,916,239 operationally tedious, inefficient, expensive and environmentally hazardous on an industrial scale.
SUMMARY AND DETAILED DESCRIPTION OF THE INVENTION
The aim of the present invention is to provide an efficient method for lactonization of statins which method avoids the use of strong corrosive acids and drastic heat conditions and gives a lactonized product of high purity and yield.
The present invention provides a novel process for converting the HMG--CoA reductase inhibitors, e.g., the open hydroxy acid forms of lovastatin, simvastatin, and analogs thereof, into their lactone forms, and is convenient to operate on an industrial scale. It allows the lactonization reaction to proceed at moderate temperatures without the use of industrially unsafe strong acids.
Specifically, the process of the present invention comprises dissolving the open hydroxy acid in its salt form (II), preferably the ammonium salt, by heating in an organic solvent at a temperature from about ambient to reflux of the solvent under anhydrous conditions, treating with a mild catalyst, as hereinafter described, at a temperature from about ambient to 50° C., precipitating the lactonized product by the addition of water and collecting the crystalline product (I) from the mixture. The reaction can be represented as follows: ##STR3## wherein R is: ##STR4## wherein R1 =H or CH3.
The mild catalysts to be used in the instant invention are the salts of organic bases with inorganic or organic acids, such as pyridine hydrobromide, pyridine hydrochloride, or pyridine p-toluene sulfonate. Most preferably, pyridine hydrobromide is used. The catalysts are used in small catalytic quantities ranging from 0.1 to 0.5 molar equivalents, preferably ranging from 0.1 to 0.25. The term "organic solvent" in this invention refers to any lower alkanol or non-alcoholic polar solvent. The lower alkanol includes those primary, secondary and tertiary alcohols having from one to six carbon atoms. Suitable lower alcohol solvents also include methyl, ethyl, n-propyl, n-butyl, isobutyl and t-butyl alcohols. Preferably, the lower alkanol solvent used in the present invention will be methyl alcohol, isopropyl alcohol or isobutyl alcohol. Most preferably, isopropyl alcohol is used.
The non-alcoholic polar solvents which may be used as the organic solvent in this invention include acetone, methyl ethyl ketone, 2-butanone, 4-methylpentan-2-one, tetrahydrofuran or acetonitrile. Mixtures of two or more lower alkanols and/or other non-alcoholic solvents can also be used.
The lactonization reaction is efficiently accomplished within about 1-2 hours. However, the length of time required will vary depending on such factors as temperature of reaction, concentration and presence or absence of stirring.
The amount of solvent is at least 1 part by volume per part of the starting material. Higher amounts of solvents and generally up to 30 parts by volume may be used. Amounts higher than 30 volumes are not useful from an economic point of view because large size reactors would be necessary.
The product obtained under the above defined conditions is highly crystalline and is easily filterable. The product is very pure (>98% HPLC purity) with much less formation of impurities as compared to the prior art procedures. It does not require further purification. Furthermore, the process is safe and environment friendly as very mild catalysts and non-drastic conditions are employed which are convenient for operation at a commercial scale.
The present invention is illustrated by the following specific examples which are not intended to limit the effective scope of the claims.
EXAMPLE-1 Preparation of 6(R)- 2- 8(S)-(2,2-dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)!-ethyl!-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. (Formula (I), R1 =CH3).
Ammonium-7- 1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(2,2-dimethylbutyryloxy)-1(S)-naphthyl!-3(R),5(R)-dihydroxyheptanoate (Formula II, R1 =CH3), (10 g, 98% pure, 0.022 moles) was suspended in isopropyl alcohol (300 ml) and refluxed for 1 hour at 81-82° C. The volume of the solvent was reduced to about half by distillation during this period to give a clear solution, which was cooled to 45° C. Dry pyridine hydrobromide (0.33 g, 0.002 moles) was added under nitrogen atmosphere and the mixture was stirred at 42-45° C. for about two hours. Reaction was monitored on TLC.
After the reaction was complete, water (160 ml) was added and the reaction mixture was stirred for 5 minutes. More water (160 ml) was then added slowly to crystallize out the lactonized product. The slurry was further stirred for one hour at 30-35° C. and then at 15-18° C. for 30 minutes. Filtration followed by washing with water (15 ml×3) and drying under vacuum afforded the title product (8.4 g) in >91% yield in pure crystalline form. Purity by HPLC>98%.
EXAMPLE-2 Preparation of 6(R)- 2- 8(S)-(2-methylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8a(R)-hexahydronaphthyl-1(S)!-ethyl!-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. (Formula (I), R1 =H).
Ammonium-7- 1,2,6,7,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-(2-methylbutyryloxy)-1(S)naphthyl!-3(R), 5(R)-dihydroxyheptanoate (Formula II, R1 =H) (30 g, 75% assay, 0.0512 moles equivalent) was suspended in isopropyl alcohol (600 ml) and refluxed at 81-82° C. for 2 hours. The volume of the solvent was reduced to about 300 ml by distillation during this period. To the clear solution thus obtained, was added catalyst, pyridine hydrobromide (2 g dry, 0.0125 moles) under nitrogen atmosphere at 50° C. The contents were further stirred at 40-45° C. for about 2 hours when the reaction was complete. Water (150 ml) was added over 10 minutes followed by stirring for 5 minutes. More water (50 ml) was added to crystallize out the lactonized product completely. Filtration, washing by water (20 ml×2) and drying in vacuo at 40-42° C. afforded the title compound as a white crystalline material (22 g, 90% assay, 95.6% yield). Purity by HPLC=98.70%.
EXAMPLE-3 Preparation of 6(R)- 2- 8(S)-(2,2-dimethylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)hexahydronaphthyl-1(S)!-ethyl!-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. (Formula (I), R1 =CH3).
Adopting the same procedure as described in Example -1 and substituting pyridine hydrochloride as catalyst, the title compound was obtained in >98% purity and 89.75% yield.
EXAMPLE-4 Preparation of 6(R)- 2- 8(S)-(2-methylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)!-ethyl!-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. ((Formula (I), R1 =H).
Following the procedure substantially as described in Example -2 and substituting pyridine hydrochloride, the title compound was prepared in over 98% yield and >97% purity.
EXAMPLE-5 Preparation of 6(R)- 2- 8(S)-(2-methylbutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)!-ethyl!-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one. (Formula (I), R1 =H)
Following the procedure substantially as described in Example -2 and substituting pyridinium p-toluene sulphonate as catalyst, the title compound was obtained in over 96% yield and 98.7% purity.

Claims (10)

We claim:
1. A process for the manufacture of a compound of Formula I: ##STR5## wherein R is: ##STR6## wherein R1 is H or CH3, which comprises dissolving a compound of Formula II: ##STR7## wherein Z is hydrogen, a metal cation, or NH4, and wherein R is as defined above, in an organic solvent by heating at a temperature from about ambient to reflux of said solvent under anhydrous conditions to obtain a solution, treating the solution with a mild catalyst at a temperature from about ambient to about 50° C., and adding water to the solution thereby causing the precipitation of the compound of Formula I.
2. The process of claim 1 further comprising collecting the compound of Formula I as a crystalline product.
3. The process of claim 1 wherein said mild catalyst is a salt of an organic base with an inorganic or an organic acid.
4. The process of claim 1 wherein said mild catalyst is pyridine hydrobromide, pyridine hydrochloride, or pyridinium p-toluene sulfonate.
5. The process of claim 1 wherein said organic solvent comprises a lower alkanol having 1 to 6 carbon atoms.
6. The process of claim 5 wherein said lower alkanol comprises a primary, secondary, or tertiary alcohol.
7. The process according to claim 5 wherein said lower alkanol comprises methyl alcohol, ethyl alcohol, isopropyl alcohol, n-propyl alcohol, n-butyl alcohol, isobutyl alcohol, or t-butyl alcohol.
8. The process of claim 1 wherein said solvent is a non-alcoholic polar solvent.
9. The process of claim 8 wherein said non-alcoholic polar solvent comprises acetone, methyl ethyl ketone, 4-methyl pentan-2-one, tetrahydrofuran, or acetonitrile.
10. The process of claim 1 wherein said organic solvent is a mixture of a lower alkanol and a non-alcoholic polar solvent.
US09/055,572 1997-10-28 1998-04-06 Process of lactonization in the preparation of statins Expired - Fee Related US5939564A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3101DE1997 IN186879B (en) 1997-10-28 1997-10-28
IN3101 1997-10-28

Publications (1)

Publication Number Publication Date
US5939564A true US5939564A (en) 1999-08-17

Family

ID=11092797

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/055,572 Expired - Fee Related US5939564A (en) 1997-10-28 1998-04-06 Process of lactonization in the preparation of statins

Country Status (2)

Country Link
US (1) US5939564A (en)
IN (1) IN186879B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030773A2 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process
WO2002094803A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce highly pure simvastatin
US6521762B2 (en) 2000-03-03 2003-02-18 BIOGAL Gyógyszergyar RT. Process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
US6562984B2 (en) 2001-03-09 2003-05-13 Synthon Bv Lactonization process
US6573392B1 (en) 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
US6573385B1 (en) 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and novel intermediates thereof
WO2003048149A1 (en) * 2001-12-03 2003-06-12 Cj Corp. Processing method of lactonization in the preparation of statins
WO2003057684A1 (en) * 2002-01-09 2003-07-17 Hanmi Pharm. Co., Ltd. Process for the preparation of simvastatin
US6603022B1 (en) 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
WO2005095374A1 (en) * 2004-03-30 2005-10-13 Lupin Ltd. An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
US20070087050A1 (en) * 2005-08-17 2007-04-19 Jansen Korinde A Orally Disintegratable Simvastatin Tablets
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820850A (en) * 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030773A2 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process
WO2001030773A3 (en) * 1999-10-27 2001-06-14 Merck & Co Inc Lactonization process
US6380401B1 (en) 1999-10-27 2002-04-30 Merck & Co., Inc. Lactonization process
US6525205B2 (en) 1999-10-27 2003-02-25 Merck & Co., Inc. Lactonization process
US6573392B1 (en) 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
US6573385B1 (en) 1999-11-11 2003-06-03 Biocon India Limited Process for manufacturing simvastatin and novel intermediates thereof
US6521762B2 (en) 2000-03-03 2003-02-18 BIOGAL Gyógyszergyar RT. Process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
US6562984B2 (en) 2001-03-09 2003-05-13 Synthon Bv Lactonization process
WO2002094803A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce highly pure simvastatin
US20030109723A1 (en) * 2001-12-03 2003-06-12 Cj Corp. Processing method of lactionization in the preparation of statins
WO2003048149A1 (en) * 2001-12-03 2003-06-12 Cj Corp. Processing method of lactonization in the preparation of statins
US6906204B2 (en) 2001-12-03 2005-06-14 Cj Corp. Processing method of lactionization in the preparation of statins
WO2003057684A1 (en) * 2002-01-09 2003-07-17 Hanmi Pharm. Co., Ltd. Process for the preparation of simvastatin
US20050080275A1 (en) * 2002-01-09 2005-04-14 Hanmi Pharm. Co., Ltd Process for the preparation of simvastatin
US6603022B1 (en) 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
WO2005095374A1 (en) * 2004-03-30 2005-10-13 Lupin Ltd. An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
US20080269508A1 (en) * 2004-03-30 2008-10-30 Milind Moreshwar Gharpure Method for Manufacture of 4-Hydroxy Pyran-2-One Derivatives
US7777056B2 (en) 2004-03-30 2010-08-17 Lupin Ltd. Method for manufacture of 4-hydroxy pyran-2-one derivatives
US20070087050A1 (en) * 2005-08-17 2007-04-19 Jansen Korinde A Orally Disintegratable Simvastatin Tablets
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin

Also Published As

Publication number Publication date
IN186879B (en) 2001-12-01

Similar Documents

Publication Publication Date Title
KR970011286B1 (en) Process for the lactonization of mevinic acid
US5393893A (en) Process for producing simvastatin and analogs thereof
US5917058A (en) Process of lactonization in the preparation of statins
EP0864569B1 (en) Process for manufacturing simvastatin from lovastatin or mevinolinic acid
US6331641B1 (en) Process for producing simvastatin
US5939564A (en) Process of lactonization in the preparation of statins
EP0864560B1 (en) Key intermediates in the manufacture of simvastatin
US6384238B1 (en) Process for the preparation of simvastatin and analogs thereof
US6521762B2 (en) Process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
EP0955297B1 (en) An improved process of lactonization in the preparation of statins
KR100322630B1 (en) Processes for Producing Simvastatin and its Intermediate
SK283319B6 (en) Process for manufacturing simvastatin from lovastatin or mevinolinic acid
EP1732912B1 (en) An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
US6573392B1 (en) Process for manufacturing simvastatin and the novel intermediates
KR100423892B1 (en) A new process of lactonization in the preparation of statins
EP1786765B1 (en) An improved process for lactonization in the preparation of statins
CZ264997A3 (en) Process for preparing simvastatin from lovostatin or mevinolinic acid
WO2005012279A1 (en) Lactonization process
AU2001241833A2 (en) A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities

Legal Events

Date Code Title Description
AS Assignment

Owner name: RANBAXY LABORATORIES, LTD., INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUMAR, YATENDRA;THAPER, RAJESH KUMAR;KUMAR, S.M. DILEEP;AND OTHERS;REEL/FRAME:009083/0727

Effective date: 19980406

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20070817